Old Web
English
Sign In
Acemap
>
authorDetail
>
Hans-Guido Holl
Hans-Guido Holl
Internal medicine
Medicine
Oncology
Progression-free survival
Progressive disease
4
Papers
3
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
BICENTRIC PILOT STUDY ON AGE-ADAPTED HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA PATIENTS > 65 YEARS - MARiTA TRIAL
2019
Hematological Oncology
Elisabeth Schorb
Benjamin Kasenda
Gabriele Ihorst
Heidi Fricker
Hans-Guido Holl
Juergen Finke
Gerald Illerhaus
Show All
Source
Cite
Save
Citations (1)
Ifosphamide and Carboplatin Based (R-DeVIC) Salvage Therapy in Patients with Relapsed/Refractory PCNSL – a Multicentre Retrospective Analysis
2018
Blood
Hans-Guido Holl
Elisabeth Schorb
Jürgen Finke
Nikolaos Vassiliadis
Benjamin Kasenda
Gerald Illerhaus
Show All
Source
Cite
Save
Citations (0)
Induction Chemo-Immunotherapy with the Matrix Regimen in Patients with Newly Diagnosed PCNSL - a Multicenter Retrospective Analysis on Feasibility and Effectiveness in Routine Clinical Practice
2017
Blood
Elisabeth Schorb
Christopher P. Fox
Benjamin Kasenda
Teresa Calimeri
Kim Linton
Jeffery Smith
Slavisa Ninkovic
Deborah Yallop
Hans-Guido Holl
Alberto Fabbri
Thomas Cummin
Gerald Illerhaus
Kate Cwynarski
Andrés J.M. Ferreri
Show All
Source
Cite
Save
Citations (2)
Einfluss von Komplementfaktor C3a und synthetischem C3a-Rezeptor-Agonist auf die C3a-Rezeptorexpression und Antitumorreaktivität von natürlichen Killerzellen
2016
Hans-Guido Holl
Show All
Source
Cite
Save
Citations (0)
1